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Background:There is no cure for autoimmune chronic inflammatory bowel disease (IBD).
IBD patients commonly use complementary and alternative medications of which the
safety, efficacy, and interaction with standard-of-care therapies are not fully known.Thus the
consequences can become life-threatening. Sulfasalazine commonly used in IBD, poten-
tially has severe adverse effects, including infertility, pulmonary fibrosis, lack of response,
and ultimately patients may require intestinal resection. We hypothesized that green tea
polyphenols (GrTP, EGCG) and sulfasalazine have similar anti-inflammatory properties.
Methods: BALB/c mice received Dextran sodium sulfate (DSS) to induce colitis (ulcerative
colitis model). Exposure of IL-10 deficient mice (BALB/c-background) to normal microbiota
provoked enterocolitis (mimics Crohn’s disease). Animals were treated with agents incor-
porated into daily diets. Control animals received sham treatment.
Results: DSS-treated animals developed severe bloody diarrhea and colitis (score 0–4,
3.2±0.27). IL-10 deficient mice developed severe enterocolitis as manifested by diarrhea,
rectal prolapse, and colonic lesions. Animals tolerated regimens (GrTP, EGCG, sulfasalazine)
with no major side effects, and further developed less severe colitis. IL-10 deficient ani-
mals became moribund on high dose, while tolerated low and Mid doses with significant
improved symptoms of enterocolitis. GrTP, EGCG, and sulfasalazine significantly amelio-
rated colonic damage and histological scores in treated animals in a similar manner (GrTP
vs. DSS p<0.05; EGCG, sulfasalazine vs. DSS p<0.01). The inflammatory markers TNFα
(3-fold), IL-6 (14-fold), and serum amyloid A (40-fold) increased in colitic animals and signifi-
cantly decreased with treatment regiments. In contrast, circulatory leptin levels decreased
in colitic animals (twofold). EGCG additionally reduced leptin levels (p<0.01) while GrTP
and sulfasalazine had no effect on leptin levels (p<0.05). Hepatic and colonic antioxidants
were significantly depleted in colitic animals and treatment regiments significantly restored
antioxidants levels.
Conclusion: GrTP and EGCG improved antioxidants levels and attenuated severity of colitis
analogous to sulfasalazine. Future studies will reveal whether polyphenols can become an
alternative/additive therapy for IBD therapy in humans.
Keywords: IBD, enterocolitis, colitis, polyphenols, EGCG, sulfasalazine, IL-10−/− mice
INTRODUCTION
Crohn’s disease and ulcerative colitis are chronic idiopathic inflam-
matory bowel diseases (IBD) mediated by immune dysfunction.
Despite advancement in humanized monoclonal antibodies and
available targeted therapies, there is still no cure for IBD. Therefore,
Abbreviations: Cox-2, cyclooxygenase 2; DSS, dextran sodium sulfate; EGCG,
(-)-epigallocatechin-gallate; GI, gastrointestinal tract; GrTP, green tea polyphe-
nols; GSH, glutathione; IBD, inflammatory bowel disease; IEC, intestinal epithe-
lial cells; IL-10, interleukin 10; LPL, lamina propria; LPS, lipopolysacchride; MΦ,
macrophage; NF-κB, transcription nuclear factor kappa B; PBL, peripheral blood
lymphocytes; ROS, reactive oxygen species; SAA, serum amyloid A; TNFα, tumor
necrotic factor; WT, wildtype.
many IBD patients remain refractory to the existing therapies
(Fiocchi, 2012). Furthermore, IBD predisposes patients to intesti-
nal surgeries and colorectal malignancy. Inflamed colonic tissue
in IBD patients (Grisham and Granger, 1988; Rezaie et al., 2007)
and models (Oz et al., 2012a) are rich in neutrophils and activated
macrophages and subsequent increased reactive oxygen (ROS) and
nitrogen (NOS) species (Oz et al., 2012b). The excess generation of
toxic radicals surpasses the intestinal antioxidant defensive ability,
thus resulting in oxidative damage (Grisham and Granger, 1988;
Oz et al., 2012a,b).
Sulfasalazine has been used as a mainstay of therapy in IBD for
decades. Sulfasalazine is a prodrug composed of 5-aminosalicylic
acid (5-ASA) and sulfapyridine linked by an azo bond that is
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poorly absorbed in the stomach and small intestine. The azo
linkage is cleaved by the azoreductases released from terminal
ileum and colonic anaerobic microbiota to form a pair of amines
with the active moiety, 5-ASA (Scheline, 1973; Oz and Ebersole,
2008, review). Sulfasalazine acts as an antioxidant against gen-
erated ROS and NOS, with metal chelating effect which reduces
oxidative burst. Sulfasalazine may protect against fibrosis by accel-
erating apoptosis in stellate cell (Oakley et al., 2005). In addition,
sulfasalazine induces T lymphocyte apoptosis, inhibits inflamma-
tory intermediates cyclooxygenase/lipoxygenase and nuclear fac-
tor kappa B (NF-kB) transcription pathway for pro-inflammatory
cytokines, and activates peroxisome proliferator-activated recep-
tor (Wahl et al., 1998; Cavallini et al., 2001; Liptay et al., 2002;
Doering et al., 2004; Rousseaux et al., 2005).
However, sulfasalazine has a double edged sword effect by gen-
erating additional oxidative stress, which may result in hepatotoxi-
city (Uko et al., 2012) and ulcerogenic potential. Furthermore, sul-
fasalazine can provoke hypospermia, and male infertility (Linares
et al., 2011), the underlying mechanisms are not fully understood
(Katsanos et al., 2012). Sulfasalazine is shown to increase thio-
barbituric acid-reactive substances (TBARS), and catalse activity
while decrease superoxide dismutase and glutathione levels in
hepatic, and kidney suggesting oxidative damage can be a mecha-
nism for nephro-and hepatotoxicity and male infertility related to
sulfasalazine treatment (Alonso et al., 2009; Linares et al., 2009).
Additionally, 5-ASA induces apoptosis of intestinal epithelia
and inhibits regeneration of colitic mucosa (Reinacher-Schick
et al., 2000; Brown et al., 2010). Some of these side effects (e.g.,
hepatotoxicity, and severe blood disorders) are due to the sul-
fapyridine portion of sulfasalazine. These patients require escala-
tion of medical therapies and surgery. Therefore, safe and effective
drugs are needed for this vulnerable population.
About 30–50% of IBD patients use some type of Complemen-
tary and Alternative Medicine (CAM) therapy (Opheim et al.,
2012) in addition to their medications whether or not discussed
with their primary care providers. However, the safety and effi-
cacy of these compounds and interaction with other drugs in use
have not been fully investigated. Therefore, the consequences can
be potentially dangerous. The range of CAM therapies include:
(i) hypnosis (Szigethy et al., 2011), (ii) acupuncture to decrease
response to stress (Rawsthorne et al., 2012), (iii) megadoses of
Vitamins and minerals, (iv) prebiotics (Oz and Ebersole, 2008; Oz
et al., 2009) (v) probiotics (Mack, 2011), and (vi) Herbal Medi-
cines (Geerling et al., 2000; Keefer et al., 2012). Amongst herbal
therapy, tea and tea extracts have received a great deal of attention
and are available over the counter (OTC). Tea (Camellia sinensis) is
an evergreen shrub which has been used for about 4000 years and
is the most consumed beverage after water (Mukhtar et al., 1992;
Sharma et al., 2007). Tea contains several components including
vitamins (B and C), minerals, and caffeine. Three types of tea
are available depending on the processing technique. Black tea is
produced by rolling and fermenting the leaves and consumed the
most (78% consumption). Green tea is prepared from steamed and
dried leaves (20% consumption). Oolong tea is an intermediate
form when leaves are semi-fermented (2% consumption).
Green tea Polyphenols (GrTP) are antioxidants and we have
previously shown them to have inhibitory effects on NF-kB
in vitro in intestinal epithelial cells (Yang et al., 2001) and anti-
inflammatory effects in IL-2 deficient mice and some aspects
of dextran sodium sulfate (DSS) induced-colitis models (Var-
ilek et al., 2001; Oz et al., 2005). GrTP are shown to have
a variety of beneficial effects including anti colorectal can-
cer possibly through decreasing the serum levels of triglyc-
eride (Shimizu et al., 2008) and promotion of apoptosis (Shi-
rakami et al., 2008; Oz and Ebersole, 2010). In addition, GrTP
blocks cyclooxygenase (Cox2) and BCL-2 activity to protect
against acetaminophen hepatotoxicity (Oz and Chen, 2008; Oz
et al., 2009), as well as LPS induced and carbon tetrahydrochlo-
ride hepatotoxicity (Chen et al., 2004). Polyphenols are bro-
ken down by the gut microbiota. Similarly, about 70–90% is
excreted into feces and the rest recovered from urine (Grif-
fiths and Smith, 1972). Polyphenols are the main component of
green tea which have received extensive attention and contains
four known catechins: (-)-epigallocatechin-3-gallate (EGCG),
(-)-epigallocatechin (EGC), (-)-epicatechin-3-gallate (ECG), and
(-)-epicatechin (EC). EGCG accounts for about 40% of the total
polyphenols in tea.
We hypothesized that the alternative therapy with GrTP and
EGCG protect against inflammatory responses in DSS induced
ulcerative colitis and in the IL-10 deficient model of sponta-
neous enterocolitis (resembling Crohn’s disease) models in a
dose dependent manner similar to the standard-of-care agent
sulfasalazine.
MATERIALS AND METHODS
The animal studies were approved and performed in accordance
with the guidelines for the care and use of laboratory animals
accredited by the American Association of Accreditation of Lab-
oratory Animal Care (AAALAC) at Veterans Administration (VA)
and Laboratory Animal Research Resource Facility at the Univer-
sity of Kentucky Medical Center in Lexington, KY, USA. Animals
were divided into groups of nine mice each (three/cage) and study
was repeated at least once. All experiments conform to the relevant
regulatory standards.
ANIMAL MODELS OF IBD
IL-10 DEFICIENT MOUSE MODEL
Interleukin-10 deficient breeding pairs in BALB/c-background
were originally obtained from Taconic/Dr. Rennick (Rennick and
Fort, 2000) and bred in our transgenic facility. Animals were
raised under microbial and pathogen-free conditions in ventilated
microisolators with HEPA-filtrated air. Animals were handled in
the biosafety cabinet with HEPA-filter and supplied with irradiated
and autoclaved food, water, bedding, and cages.
In addition, 5-week-old male BALB/c (wildtype-background)
mice were purchased from Harlan Laboratories (Indianapolis, IN,
USA) and housed in micro-filter top cages and acclimatized for
1 week prior to the experiment. The IL-10 deficient mice were co-
housed with wildtype mice in conventional condition, with free
access to water and food (Harlan Teklad Laboratory Diet, Madison,
WI, USA) and kept in a room with a 12 h light/dark cycle.
Colitis induction
Enterocolitis model. Enterocolitis was induced in IL-10 deficient
mice by exposure to the normal gut microbiota. Therefore, IL-10
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deficient male pups were weaned at 3 weeks of age, and at 4 weeks
were transferred into the conventional facility in a room with
unsterilized and filter top cages to reduce aerosolized contami-
nate. Cages were lightly seeded with contaminated (used) bedding
from the same age BALB/c wildtype-background. This ensured
rapid gut colonization with the microbiota, thus provoking intesti-
nal inflammation and enterocolitis which mimic Crohn’s disease
(Rennick and Fort, 2000; Oz et al., 2004).
Colitis model. Colitis was induced exclusively in BALB/c WT
mice by oral ingestion of 3% DSS for seven consecutive days
and the outcome was assessed by the clinical disease index,
inflammatory mediators, and histological grading scores.
Green tea polyphenols. Green tea polyphenols containing >98%
pure polyphenols analyzed with high-performance liquid chro-
matography (HPLC) were purchased from LKT Laboratories, Inc.
(St. Paul, MN, USA). HPLC analysis of the GrTP extracts revealed
the percentage composition of the polyphenols (four catechins) of
interest as follow: Epicatechin-gallate (EC 35%), epigallocatechin
(EGC 15%), epicatechin-gallate (ECG 4%), and epigallocatechin-
gallate (EGCG 38%). The most prevalent individual polyphenolic
constituent, EGCG (98% purity) attributed for GrTP therapeutic
effects was purchased from Sigma Aldrich (St. Louis, MS, USA).
Sulfasalazine was purchased from Sigma Aldrich (St. Louis, MS,
USA). Controls received vehicle sham treatment (sucrose). The
compounds were incorporated into daily diet for the duration of
the study (10 days for colitis). Animals consumed the diet with
no significant difference compared the sham vehicle. DSS animals
were treated with GrTP High (1%), or sulfasalazine (50 mg/kg)
incorporated into diet. EGCG was calculated according the con-
stituent of GrTP (∼40%) and given at different doses of High
(0.5%), Mid (0.25%), and Low (0.12%) in daily diet. IL-10 defi-
cient mice in conventional environment (as mentioned above)
were treated with three different doses of GrTP at High (1%),
Mid (0.5%), and Low (0.25%) for the duration of enterocolitis
experiment. Sham control animals received sucrose alone. IL-10
deficient animals on High dose lost weight and became moribund,
therefore were humanely eliminated. However, those IL-10 defi-
cient mice on Mid and Low dose, tolerated the treatments for the
10 weeks duration of the study. At the end of experiments, animals
were humanely euthanatized and blood and tissue samples were
collected.
IL-10 deficient enterocolitis model (n= 9)
To establish the Enterocolitis Model
(A) Untreated normal mice kept in transgenic facility.
(B) Untreated mice exposed to normal gut microbiota in conven-
tional faculty
GrTP and Enterocolitis Model
(A) Untreated mice exposed to normal gut microbiota in conven-
tional faculty
(B) GrTP High dose (1%) treated mice exposed to normal gut
microbiota in conventional faculty (were eliminated due to
the morbidity)
(C) GrTP Mid dose (0.5%) treated mice exposed to normal gut
microbiota in conventional faculty
(D) GrTP Low dose (0.25%) treated mice exposed to normal gut
microbiota in conventional faculty
BALB/c mice and DDS induced-colitis model
GrTP/EGCG and BALB/c Mice (n= 3)
(A) Untreated normal mice
(B) GrTP High dose (1%) treated mice
(C) EGCG High dose (0.5%) treated mice
(D) EGCG Mid dose (0.25%) treated mice
(E) EGCG Low dose (0.12%) treated mice
(F) Sulfasalazine (50 mg/kg) treated mice
GrTP and DSS colitis model (n= 9)
(A) Untreated normal mice
(B) DSS-treated colitis mice
(C) DSS+GrTP High dose (1%) treated mice
(D) DSS+ EGCG High dose (0.5%) treated mice
(E) DSS+ EGCG Mid dose (0.25%) treated mice
(F) DSS+ EGCG Low dose (0.12%) treated mice
(G) DSS+ sulfasalazine (50 mg/kg) treated mice
The clinical disease. Animals were monitored for appearance,
weight loss, consistency of stool, diarrhea, presence of blood in
the stool, prolapse, survival, and anemia as expressed by the
hematocrit, and colonic and splenic weight and length were
measured.
Blood and plasma isolation. Immediately after euthanasia, blood
was collected via the right ventricle of the heart into the lightly
heparinized syringes and kept on ice. Plasma was separated by
centrifugation at 5000× g for 5 min at 4° C. Samples were stored
at−80° C until further analysis.
Colonic histopathology. Colonic tissues were flushed with ice
cold phosphate-buffered saline (PBS pH 7.2) and a portion from
ascending and descending colonic tissues were fixed in 10%
buffered formalin for histological examination. The remainder
was snap-frozen in liquid nitrogen and stored at −80 °C. The
formalin fixed sections were sliced at 5µm then processed and
stained with hematoxylin and eosin (H&E) and evaluated for
the histopathology under light microscopy. Severity of colitis was
assessed with a histological semi-quantitative grading score (Oz
et al., 2005, 2007). The scores were based on histological fea-
tures with a numeric value (0–4) assigned according to the tissue
involvement and severity of lesions that corresponded to either of
following criteria.
Grade 0 – No detectable lesions, no inflammatory cells, normal
mucosal appearance.
Grade 1 – Few focal inflammatory infiltrate in the mucosa and
lamina propria, epithelial hyperplasia (25% involved).
Grade 2 – Mild inflammation with a few multi-focal expansion
of monocytes, neutrophils (PMN), epithelial hyperplasia into the
mucosa (50% involved).
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Grade 3 – Moderate inflammation with multi-focal expansion of
mono, PMN, crypt abscess, epithelial hyperplasia into the mucosa
(75% involved).
Grade 4 – Anal prolapse, severe diffused inflammation with
crypt abscess, mono, PMN, transmural epithelium disruption,
and ulceration few mucin (over 75% involved).
Tissue preparation for antioxidant determination. Tissue
homogenates (10% w/v) were prepared in 5% metaphosphoric
acid, using all-glass Tenbroeck homogenizers, and kept on ice
(Chen et al., 2000; Oz et al., 2004). After standing for 20–
40 min, the homogenates were centrifuged for 1 min (10,000 g )
and the acid-soluble fractions were collected for measurement
of sulfhydryl (SH) and disulfides (SS). GSH, GSSG, and other
thiols, cysteine, and cystine were simultaneously quantified by
HPLC with dual electrochemical detection (HPLC–DEC). Sam-
ples (20µl) were injected on to a 250× 4.6 mm, 5µm particle, C18
column (Val-U-Pak HP, fully end-capped ODS; Chrom Tech Inc.,
Apple Valley, MN, USA). The injected samples were eluted isocrat-
ically with a mobile phase consisting of 0.1 M monochloroacetic
acid, 2 mM heptane sulfonic acid (ion-pairing reagent), and 2%
acetonitrile at pH 2.8 and delivered at a flow rate of 1 ml/min.
The compounds were detected in the eluent with a Bioanalyti-
cal Systems model LC4B dual electrochemical detector, using two
Au-Hg electrodes in series with potentials of −1.2 and 0.15 V for
the upstream and downstream electrodes, respectively. Current
(nA) was measured at the downstream electrode. Analytes were
quantified from peak area measurements using authentic external
standards.
Inflammatory biomarkers immunoassays. Cytokines were assayed
in animals according the manufacture’s recommended protocol.
The concentrations of IL-1β, IL-6, TNFα, and leptin were mea-
sured with Quantikine M ELISA kits obtained from R&D Com-
pany (Minneapolis, MN, USA). Serum amyloid A (SAA) analyzed
with Kits from BioSource (Camarillo, CA, USA).
Statistical analysis. Data was analyzed using ordinary and
repeated measures ANOVA. It was further analyzed by post hoc test
(Tukey compared all pairs) for statistical difference using Graph-
Pad Instat and Prism Software for Windows (San Diego, CA, USA).
Statistical significance between groups considered to be significant
was set at p< 0.05. Results are expressed as the mean± SEM unless
otherwise stated.
RESULTS
BALB/C wildtype animals tolerated GrTP, EGCG, and sul-
fasalazine in their daily diets with no severe side effects. Weight
loss is a hallmark of colitis and colitic animals lost 8% of their
body weight. GrTP (−2.5%) and Sulfasalazine (−5%) partially
improved the weight loss in colitic animals, while, Mid and Low
doses of EGCG had no effect on preserving animals’ weight
(−8%). In contrast, High dose EGCG consumption further accel-
erated weight loss (−12%) (Figure 1). Colitic animals developed
anemia due to bloody diarrhea, manifested with pale mucosa
and a significant reduction in hematocrit (Control 41.5± 1.5 vs.
colitic 25.2± 1.7 p< 0.05). EGCG and GrTP partially improved
anemia and the hematocrit value. In contrast, sulfasalazine treat-
ment further triggered anemia and the reduction in the hematocrit
FIGURE 1 | Percent body weight loss in DSS-induced colitis compared
to the normal control animals. Colitic mice lost body weight and animals
on High dose EGCG therapy showed the most weight loss. Mid and Low
doses of EGCG had no effect on body weight. In contrast, GrTP and
Sulfasalazine partially improved the body weight loss.
value (21.5± 2 p< 0.01) (Table 1). EGCG and GrTP administered
to naïve control animals had no negative effect on the colonic
weight or length. Colonic length became shortened (35%) and
colonic weight increased in colitic animals due to the accumu-
lation of inflammatory cells and EGCG partially improved the
length (9%) with no effect on weight compared to colitic animals
(Table 1). IL-10 deficient animals tolerated Low and Mid doses of
GrTP and showed significantly improved enterocolitic symptoms
while, lost weight and became moribund on high dose and were
terminated.
CIRCULATING INFLAMMATORY MARKERS
Colitis increased TNFα levels in blood circulation and sul-
fasalazine was most effective in normalizing TNFα release (vs. col-
itis p< 0.01). Sulfasalazine and to a lesser extent GrTP and EGCG
(p< 0.05) decreased this pro-inflammatory cytokine (Figure 2A).
Similarly, Blood levels of the multifunctional pro-inflammatory
cytokine, IL-6 were significantly increased in colitic animals and
EGCG and GrTP (p< 0.05) and sulfasalazine therapy (p< 0.01)
significantly reduced secretion of IL-6 levels in treated animals
(Figure 2B).
Serum amyloid A an inflammatory marker and an acute
phase reactive protein was significantly increased in colitic ani-
mals (Control vs. colitic animals p< 0.01) and Mid dose EGCG
and sulfasalazine partially but significantly (p< 0.05) amelio-
rated this circulating inflammatory marker (Table 1). GrTP
therapy had a partial effect on the SAA which did not reach
significance.
Leptin production, the marker of satiety, energy and expen-
diture, with central role in inflammatory response and immune
defense was drastically decreased in colitic animals (p< 0.05) and
EGCG consumption further reduced the leptin levels while GrTP
and sulfasalazine had no additional affect on leptin regulation
(p< 0.01) (Figure 3).
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Table 1 | Comparison of inflammatory markers and antioxidants between sham normal controls, DSS-induced colitic animals, and those treated
with dose escalating EGCG or sulfasalazine.
Control DSS EGCG high EGCG mid EGCG low Sulfa
Hematocrit 41.5±1.5*# 25.2±1.7* 31.9±3.4 28.8±3 30.9±2 21.5±2#
SAA µg/ml 8±2# 327±19#* 261±44 258±4* 298±7 242±53*
Colonic length 9.7±0.6* 6.3±0.2 6.9±0.2 6.7±0.1 6.9±0.2 ND
Colonic weight 120±5.7* 159±9.0 166.8±7.0 151±4.5 154±5.4 ND
Colonic GSH 2904±462#* 168±32# 1208±405* 515±215* 227±63 147±32#
Ileac GSH ND 305±118∧ 2443±261∧ 2226±163∧ 1338±149* 600±171@
Hepatic GSH 8188±219 6283±897* 7466±235 5967±407 6233±565 6419±280
Hepatic GSSG 433±76 623±99* 182±49 400±76 315±106 386±72
Hepatic ratio 19*# 10* 41# 15 20 17
Hepatic Cys 175±9* 279±14#* 148±18# 246±36 218±9 241±12*
Hepatic CSSC 51±10 38±7 39±6 51±14 46±15 75±11
ND, not determined.
DSS administration reduced the Colonic length (<0.05) and increased the Colonic weight (<0.05) due to the inflammatory response compared the normal controls
and treatments had no significant effects.
@Ileac GSH is partially increased by the sulfasalazine therapy but did not reach significance p=0.05.
Oxidized (SS) and reduced (SH) sources of GSH are presented by nmol/g of tissue.
Hepatic Cys (cysteine) and CSSC (cystine) levels are presented by nmol/g of tissue.
DSS, dextran sodium sulfate-induced colitic animals.
Sulfa, sulfasalazine treated animals.
Hepatic ratio, represents ratio of liver reduced GSH/oxidized GSSG.
*p< 0.05, #p<0.01, ∧p<0.001.
FIGURE 2 | (A) DSS-induced colitic animals had increased
secretion of inflammatory cytokine TNFα in blood circulation.
EGCG therapy significantly prevented increased secretion
(p<0.05) and sulfasalazine normalized TNFα secretion.
(B) Multifunctional cytokine, IL-6 was drastically increased in
DSS-induced colitic animals. EGCG (p<0.05) and sulfasalazine
(p<0.01) significantly reduced elevated level of this inflammatory
marker in treated animals.
COLONIC LESIONS
Dextran sodium sulfate-induced severe colitis manifested with
infiltrations of immune and inflammatory cells including
neutrophils and macrophages, loss of crypts, and ulcerations
scored 3.2± 0.27 p< 0.001 (zero-normal control to four severe).
Sulfasalazine and Low dose EGCG similarly (p< 0.01) and GrTP
(p< 0.05) to a lesser extent attenuated the pathological lesions and
preserved colonic microstructure (Figure 4).
ANTIOXIDANT ACTIVITY
Glutathione (GSH) is the most essential intracellular element to
protect intestinal epithelial cells against ROS, and to preserve
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FIGURE 3 | Circulating leptin level significantly decreased in
DSS-induced colitic animals (p<0.05) and EGCG further reduced the
leptin levels (DSS vs. EGCG<0.05), while GrTP and sulfasalazine had
no significant effect on leptin levels (vs. DSS>0.05).
FIGURE 4 | Pathologic scores (zero-normal to four most severe) in
colitic animals. DSS-induced severe colonic pathology. Low dose EGCG
and sulfasalazine similarly attenuated pathological lesions (p<0.01). To a
lesser extent, GrTP (p<0.05) ameliorated the colonic lesions.
the gut integrity. Hepatic GSH (p< 0.01) which is the main
source of gut antioxidant and colonic GSH (p< 0.05) was dras-
tically depleted in the colitic animals. EGCG as well as GrTP
significantly improved intestinal GSH. In contrast sulfasalazine
had minor restorative effect on intestinal GSH (Table 1). The
oxidized glutathione (GSSG) increased in colitic animals indi-
cating accumulation of oxidative radicals in these organs and
improved with therapies (Table 1). The ratio of hepatic reduced-
to-oxidized glutathione, GSH/GSSG, was decreased to about 1/2 of
the normal control levels indicating DSS-induced colitis as a global
oxidative stress model. GrTP, Low dose EGCG, and sulfasalazine
treatment similarly normalized hepatic glutathione concentration
ratio. In contrast, High dose EGCG treatment resulted in drastic
(fourfold) increases in the hepatic glutathione ratio, demonstrat-
ing exaggerated global antioxidant activity of the High dose EGCG
(Table 1).
GrTP AND SPONTANEOUS ENTEROCOLITIS
We further examined efficacy of GrTP against enterocolitis in
IL-10 deficient mice exposed to normal gut microbiota. Animals
became anemic (Figure 5A) and showed increased colonic weight
(309± 39) and splenic length (1.7± 0.05) due to accumulation of
inflammatory cells and enterocolitis (Figure 5B). IL-10 deficient
animals tolerated Low and Mid doses of GrTP with significant
improvement in their enterocolitis symptoms for the duration of
experiment. While, animals on High dose lost weight and became
moribund and were terminated. GrTP significantly improved ane-
mia, decreased colonic weight (254± 17), and normalized splenic
length (1.5± 0.04 p< 0.05). In addition, IL-10 deficient mice
had significantly high SAA (100 times) and IL-1β (200 times)
compared to those kept at transgenic conditions. GrTP had no
significant effect on IL-1β with a partial effect on SAA in this
model (data not shown).
Sham treated IL-10 deficient mice (Sham-Co) kept in the
conventional environment developed severe enterocolitis mani-
fested with moderately severe pathological lesions (score 2.4± 0.3)
including infiltration of inflammatory and immune cells lamina
propria, ulceration, and rectal prolapse when compared to those
control littermates kept in transgenic environment (0.3± 02, data
not clown). Colonic lesions were significantly improved in GrTP
treated animals (Mid GrTP 0.75± 0.3 p< 0.01, and Low dose
1± 0.2 p< 0.05) when compare the sham controls demonstrat-
ing GrTP potential effect in treatment and/or maintenance in IBD
models (Figure 5C).
DISCUSSION
Despite advances in humanized monoclonal antibodies and avail-
able targeted therapies, there is no cure yet for IBD. Biologic ther-
apies, such as monoclonal antibody treatment are prohibitively
expensive and have potential adverse effects including infections
with fungi, JC virus, and tuberculosis. Many IBD patients also
remain refractory to the existing therapies. Furthermore, IBD pre-
disposes patients to intestinal surgeries and colorectal malignancy.
Sulfasalazine is a standard care for treatment and maintenance in
IBD also has severe adverse effects including hepatotoxicity (Uko
et al., 2012), ulcerogenic and male infertility potential (Linares
et al., 2011), as well as blood disorders in patients (Katsanos et al.,
2012). Therefore, many of these patients seek CAM for symptom
relief and improved quality of life.
Polyphenols are one of the most used herbal therapies avail-
able and have anti-inflammatory effect due to their antioxidant
effects, alteration in the cell signaling, and particularly inhibition
of the nuclear factor NF-κB pathway. Using IBD as a model of
inflammation, we explored anti-inflammatory effects of the prin-
cipal CAM, namely, GrTP and its most abundant cathechin EGCG,
compared to the standard care, sulfasalazine treatment in murine
colitis models. The susceptibility of mice to DSS-induced colitis
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FIGURE 5 | IL-10 deficient mice when exposed to the normal colonic
microbiota (Sham-Control) developed enterocolitis in conventional
environment. (A) IL-10 deficient mice became anemic with low hematocrit
(Sham-Control) and GrTP significantly improved hematocrit in treated animals.
(B) IL-10 deficient mice had enlarged splenic tissue due to infiltration of
inflammatory cells and GrTP significantly reduced the inflammatory response.
(C) IL-10 deficient mice developed spontaneous enterocolitis and rectal
prolapsed. GrTP significantly ameliorated the pathological scores.
and, polyphenols in specific EGCG-mediated anti-inflammatory
action in this model have much in common with the similar
phenomena observed with sulfasalazine.
While, colitic animals develop bloody diarrhea and anemia
as IBD cardinal signs, GrTP and EGCG therapy were effective
in improving hematocrit values. In contrast, sulfasalazine treat-
ment further aggravated anemia in animals conceivably due to
its adverse hemolytic effects as reported in IBD patients (Stein
and Hanauer, 2000). In this study, EGCG was calculated accord-
ing to the total amount of constituent present in the GrTP and
administered at different doses of High (1), Mid (1/2), and Low
(1/4) in daily diet. The Low dose EGCG appeared to be safe and
to have the most effect on reducing colonic pathological lesions,
normalizing global antioxidants ratio, partially improving colonic
length and weight, without causing weight loss. However, Low dose
was least beneficial in reducing SAA or in inhibiting reduction in
leptin levels. While, GrTP normalized antioxidants, partially pro-
tected animals against weight loss and elevated TNFα but was
less effective against colonic pathology as compared to Low dose
EGCG.
In mice [3H](−)-EGCG is absorbed easily from the digestive
tract and distributed widely into various organs, and excreted in
the urine (6.4–6.6%) or feces (37.7–33.1%) within 24 h (Sug-
anuma et al., 1998). In this study colonic GSH significantly
decreased in colitic animals and improved in a dose dependent
manner by EGCG treatment (DSS vs. High, Mid doses <0.05).
However, sulfasalazine had no significant effect on the intestinal
GSH. Of interest, the ratio of hepatic reduced-to-oxidized glu-
tathione, GSH/GSSG, in colitic animals was decreased to about
1/2 of the amount in normal controls representing the DSS-
induced colitis as a global oxidative stress model. Sulfasalazine,
GrTP, and Low dose treatment normalized the hepatic glutathione
ratio and the reversal of this important aspect of colitis in these
models. Interestingly, High dose EGCG treatment caused fourfold
increases in the hepatic glutathione ratio, demonstrating exag-
gerated global antioxidant imbalance presumably predisposing
animals to excess weight loss with no improvement in colonic
pathology.
In addition, EGCG and GrTP have been reported to have
antimicrobial effects and to disrupt bacterial growth (Steinmann
et al., 2013). In this study, GrTP and Low dose EGCG may have
exerted their anticolitic effects through a combination of antimi-
crobial properties mucosal immunity and gut cleansing as well as
antioxidants and anti-inflammatory action through inhibition of
NF-kB activation and further IKK activity.
Leptin, an endocrine cytokine is a 16 kDa protein encoded by
the ob gene which plays a central role in the maintenance of body
weight and energy balance (Gaetke et al., 2002a). Leptin is secreted
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by the white adipocytes (Gaetke et al., 2002b,2003) to regulate food
intake and metabolism, while its action is controlled centrally by
the hypothalamus (Zhang et al., 1994). Leptin regulates energy
metabolism by increasing energy expenditure and decreasing food
intake and body weight. The serum leptin concentration is linearly
related to fat mass in ad libitum fed mice (Schwartz et al., 1997) and
humans (Tuzun et al., 2004). Serum leptin rapidly declines with
food restriction and is elevated with feeding (Schwartz et al., 1997;
Gaetke et al., 2002a,b, 2003; Tuzun et al., 2004). Leptin deficiency
affects both the innate and acquired immune systems (Mackey-
Lawrence and Petri, 2012) as children and mice with congenital
leptin or leptin receptor deficiency are reported to be susceptible
to infections. The serum level of leptin is dysregulated in obesity
(Schwartz et al., 1997) and during the active state of IBD (Tuzun
et al., 2004). Leptin may present a potential mediator of inappro-
priate satiety and lipid dystrophy as well as deregulated immune
response to altered gut microbiota in IBD patients. In this study
colitic animals had significantly lower leptin levels. These findings
are in accordance with leptin deficiency observed in other inflam-
matory diseases, including alcoholic hepatitis in mouse model
(Tan et al., 2012). Additionally, Leptin has been shown to mediate
resistance to enteric infection Entamoeba through its direct actions
on intestinal epithelium which requires leptin receptor signaling
through both the STAT3 and SHP2/ERK pathways (Guo et al.,
2011). In the current study, GrTP and sulfasalazine had no effect
on leptin levels. However, EGCG further reduced blood concen-
tration of Leptin and High dose mediated additional weight loss
possibly by blocking the appetite and decreasing food intake in
colitic animals.
Our results have shown that 50 mg/kg sulfasalazine was suf-
ficient to exert its protective effect against DSS-induced colitis.
In contrast others reported that sulfasalazine at 10–20 mg/kg
orally or IP did not prevent weight loss nor reduced diarrhea or
gross pathology score in Trinitrobenzenesulfonic acid (TNBS)-
induced colitis (Radi et al., 2011). This could be attributed to the
insufficient drug dose used in the TNBS model against IBD.
Overall, these compounds had limited protective effects on
DSS-induced colitis since colitis in general involves several
key players including gut mucosal innate immune response,
macrophage activation, ROS generation, and inflammatory
response with subsequent loss of epithelia integrity, and increased
luminal Gram-negative microbiota. Previously we and others have
shown that GrTP inhibited signaling pathways involved in inflam-
mation, including NF-kB in intestinal cells (Yang et al., 2001) and
in IBD models (Varilek et al., 2001; Oz et al., 2005) and activated
protein-1, AP-1(Abboud et al., 2008), which are key elements in
production of pro-inflammatory mediators. Recently a mixture
of EGCG and piperine was reported to protect against lipid per-
oxidation, neutrophils accumulation in DSS-induced colitic mice,
while superoxide dismutase and glutathione peroxidase showed an
increased activity in treated animals (Bruckner et al., 2012). To our
knowledge this is the first report indicating: (a) GrTP to preserve
gut microstructure and to protect against enterocolitis in IL-10
deficient model; (b) High dose EGCG consumption to provoke
exaggerated global antioxidants and excess weight loss, rendering
ineffective against colitis; (c) GrTP and Low dose EGCG to protect
against colitis similar to the standard-of-care sulfasalazine, and to
improve anemia.
CONCLUSION
Green tea polyphenols and Low EGCG improved antioxidants
pools, decreased inflammatory cytokines and attenuated the sever-
ity of colitis in a manner similar to that of sulfasalazine. Thus
polyphenols may become an alternative/additive therapy for IBD
therapy and future human clinical trials of the polyphenols in IBD
patients are warranted.
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